Revenue Breakdown
Composition ()
No data
Revenue Streams
Profitability & Margins
Evaluating the bottom line, Zevra Therapeutics Inc maintains a gross margin of 94.04%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 15.90%, while the net margin is -2.09%. These profitability ratios, combined with a Return on Equity (ROE) of 34.81%, provide a clear picture of how effectively ZVRA converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, ZVRA competes directly with industry leaders such as ADCT and AQST. With a market capitalization of $501.61M, it holds a significant position in the sector. When comparing efficiency, ZVRA's gross margin of 94.04% stands against ADCT's 92.68% and AQST's 64.82%. Such benchmarking helps identify whether Zevra Therapeutics Inc is trading at a premium or discount relative to its financial performance.
